ZELTIQ® Aesthetics, Inc. (Nasdaq: ZLTQ), is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. The Company’s first commercial product, the CoolSculpting® system, is designed to selectively reduce stubborn fat bulges that may not respond to diet or exercise. The technology, based on the scientific principle (Cryolipolysis®) that fat cells are more sensitive to cold that the overlying skin and surrounding tissues, is the subject of more than 120 podium presentations and more than 30 published articles around the world. Drs. Manstein and R. Rox Anderson at the Wellman Center at Massachusetts General Hospital, a teaching affiliate for Harvard Medical School, conducted initial Cryolipolysis research.
Since ZELTIQ’s founding in 2005, the company has strategically grown the CoolSculpting brand to become the #1 non-invasive fat reduction procedure with millions of treatments performed to date. In the U.S. alone, more than 28.6 million people are interested in the CoolSculpting procedure for fat reduction. It generates unprecedented industry buzz, securing hundreds of headlines and leveraging social media presence, generating billions of consumer impressions and a 97% favorable online brand sentiment rating. Additionally, over 150,000 people visit the CoolSculpting website each month with 35% of them utilizing the “Find-a-Physician” locator. CoolSculpting is available in over 70 countries worldwide and the Company continues to introduce new applicators that enable more parts of the body to be treated.
In 2015, ZELTIQ was recognized for the second consecutive year on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunication, life sciences, and clean technologies companies – both public and private – in North America.